EU country and CE Marking

In May 2004, the European Union expanded to 25 countries representing 22 different languages.

Three additional countries (indicated with a * below), although not officially part of the European Union, comprise what is know as the European Economic Area (EEA).

Switzerland** is not an EU member nor a signatory of the EEA, but has incorporated the MDD and IVDD into their national law. All require CE marking for Medical Devices and IVD.

They include:
AUSTRIA
LIECHTENSTEIN*
BELGIUM
LITHUANIA
CYPRUS
LUXEMBOURG
CZECH REPUBLIC
MALTA
DENMARK
NORWAY*
ESTONIA
POLAND
FINLAND
PORTUGAL
FRANCE
SLOVAKIA
GERMANY
SLOVENIA
GREECE
SPAIN
HUNGARY
SWITZERLAND **
ICELAND*
SWEDEN
IRELAND
THE NETHERLANDS
ITALY
UNITED KINGDOM
LATVIA

Comments

Post a Comment

Popular posts from this blog

Inflammatory Bowel Disease an Independent Risk Factor for MI

Image
Patients with inflammatory bowel disease (IBD) are at significantly higher risk for myocardial infarction (MI), particularly younger patients and women, compared with the general population, new research suggests.

The study emphasizes the need for closer monitoring and aggressive attention to cardiovascular risk factors, say the researchers.

"Patients with IBD who present with any cardiovascular complaints, including chest pain or shortness of breath, should be thoroughly evaluated by their physicians for a potential heart condition," lead investigators, Muhammad Panhwar, MD, and Mahazarin Ginwalla, MD, Harrington Heart and Vascular Institute, University Hospitals Cleveland Medical Center, Ohio, advised in an email to theheart.org | Medscape Cardiology.

"Our hope is that this study prompts clinicians who care for IBD patients to start thinking about IBD as an additional risk factor for heart disease and to also screen them and treat their risk factors aggressively,&q…
Read more

The Council of the European Union has decided that the European Medicines Agency (EMA) will be relocated to the City of Amsterdam.

Image
The Council of the European Union has decided that the European Medicines Agency (EMA) will be relocated to the City of Amsterdam. The Dutch government proudly welcomes the Agency, its staff and their families to the Netherlands.

We are dedicated to safeguard the continuity of EMA’s important work for all European patients during and after its relocation. Our key objective is to ensure that the Agency can continue to function throughout the relocation process without disruption.

The Dutch government and the Amsterdam Metropolitan Area will begin to initiate the proposed transition activities immediately after the decision on relocation, in close cooperation with EMA.

Watch the movie
Read more

What makes prostate cancer aggressive? Or not so....Study investigates

By pinpointing a genetic mechanism for aggressiveness in prostate cancer, researchers have paved the way for new treatments for advanced stages of the disease.
Scientists find possible cause of 'aggressiveness' in prostate cancer. They suggest that the finding could help predict disease aggressiveness, improve personalized treatments, and "open the door" to precision medicine for advanced prostate cancer.
In a study paper now published in the journal Cell, they describe how they investigated a genomic variant known to be linked to aggressive prostate cancer.
Using state-of-the-art tools, they confirmed the link in a large group of people with prostate cancer.
They also identified how the variant influences a genetic circuit involving three genes that could potentially drive the disease to an "incurable stage."
The genomic variant is a difference in a DNA building block located in chromosome 19q13 that is known as the "single nucleotide polymorphis…
Read more